The Asthma Drug Crashing Dupixent's Biggest Party

Safety-wise, no new red flags. The side effect profile looked consistent with what doctors already know from Tezspire's use in asthma.

Why This Is About More Than One Disease

Tezspire is already a blockbuster. It pulled in $1.94 billion in 2025 sales for its asthma indication alone. In Q2 2026, Amgen reported $486 million in quarterly revenue, a 42% jump year over year. The growth trajectory is steep and getting steeper.

But AstraZeneca and Amgen aren't content to let Tezspire be a one-trick pony. The CROSSING results represent the clearest step yet in a multi-indication strategy that analysts believe could push peak sales above $4 billion. EoE would be the drug's third major indication, after severe asthma and chronic rhinosinusitis with nasal polyps.

Think of it like a franchise restaurant adding new locations. The kitchen (manufacturing, safety data, doctor familiarity) is already built. Each new indication is just another storefront generating revenue from the same core product.

Upstream vs. Downstream: The Science That Sets Tezspire Apart

To understand why this matters competitively, you need to know how these drugs work differently.

Dupixent blocks two specific inflammatory signals called IL-4 and IL-13. Think of it as shutting off two faucets that are flooding the bathroom. Effective, targeted, proven.

Tezspire takes a different approach. It blocks TSLP, a protein that sits higher up in the inflammatory chain. TSLP is more like the water main feeding those faucets (and several others). By blocking TSLP, tezepelumab can theoretically dampen multiple inflammatory pathways at once, not just the IL-4/IL-13 route.

Whether that upstream mechanism translates into meaningfully better outcomes for EoE patients is still an open question. Head-to-head trials don't exist yet. But the theoretical appeal is real: one drug targeting the root of the problem rather than individual branches.

Dupixent Isn't Going Down Without a Fight

Let's be clear about the competitive reality. Dupixent is a juggernaut. Sanofi reported €5.15 billion in Q2 2026 sales across all indications, and the drug is approved in over 60 countries. In EoE specifically, it leads the U.S. market by a wide margin and has the broadest label of any biologic in the space, covering patients as young as one year old.

The current EoE market is described as "moderately concentrated," with only three branded options: Dupixent, Takeda's Eohilia (a budesonide suspension approved in 2024), and a European budesonide tablet. That's it. There isn't exactly a crowded field here.

So Tezspire isn't displacing Dupixent tomorrow. It isn't even approved for EoE yet. AstraZeneca and Amgen still need to file with the FDA, navigate the review process, and negotiate payer coverage. Those steps take time.

But the signal is unmistakable. Dupixent's monopoly on biologic treatment for EoE has an expiration date.

The Bigger Picture for Patients

Beyond the corporate chess match, there's genuine unmet need here. Many EoE patients don't respond adequately to proton pump inhibitors. Others can't maintain elimination diets long-term (try avoiding wheat, dairy, eggs, soy, fish, and nuts forever; it's brutal). Topical steroids help some patients but aren't a universal fix.

Having a second biologic with a different mechanism of action would give gastroenterologists another tool when the first-line options fall short. Competition also tends to drive better pricing and broader access, which matters for a chronic disease requiring long-term treatment.

What Comes Next

AstraZeneca and Amgen will almost certainly move toward an FDA filing based on these results. The timeline for a potential approval likely stretches into 2027 or beyond, depending on how quickly they submit and whether the agency requires additional data.

In the meantime, Wall Street will be watching for two things: how the companies position Tezspire's EoE data at upcoming medical conferences, and whether the differentiated mechanism of action translates into a compelling commercial story against an entrenched Dupixent.

For a drug already growing at 42% year over year, adding a whole new disease to its resume could be the catalyst that turns a blockbuster into a mega-blockbuster. And for the hundreds of thousands of patients struggling to swallow their dinner, another option can't come soon enough.

The Cancer That Disappeared in Every Single Patient

GSK's dostarlimab just won FDA approval for a specific type of rectal cancer after trial results that stunned the oncology world: a 100% clinical response rate in early cohorts. For eligible patients, it could mean beating cancer without chemo, radiation, or surgery.